Heinemann L, Starke A A, Heding L, Jensen I, Berger M
Department of Nutrition, Heinrich-Heine-University Düsseldorf, FRG.
Diabetologia. 1990 Jun;33(6):384-6. doi: 10.1007/BF00404644.
Recombinant DNA technology allows the production of insulin analogues with faster absorption rates from subcutaneous tissue as compared to conventional human regular insulin. We report the time-action profiles of 12 U subcutaneously injected insulin analogues (B9Asp + B27Glu or B10Asp) as evaluated against human regular insulin by means of the euglycaemic clamp technique (blood glucose 5.0 mmol/l) in healthy men. After injection of 12 U of either insulin preparation identical values were found for maximal insulin action (maximal glucose infusion rate, time to peak action), total amount of glucose infused as well as area under the curve of glucose infusion rate. Half-maximal glucose infusion rate was reached significantly earlier after injection of modified insulins (mean +/- SD 38 +/- 7 and 43 +/- 5 min) as compared to regular insulin (56 +/- 14 min, p less than 0.01). Forty-five min after injection of both insulin analogues glucose infusion rate had increased by 7.4 +/- 1.8 or 6.1 +/- 1.8 mg.kg-1.min-1, reflecting 83 +/- 27 or 67 +/- 15% of maximal regular insulin action. In conclusion, the two tested insulin analogues showed similar action profiles, but a significantly faster onset of action as compared to regular insulin.
与传统的人常规胰岛素相比，重组DNA技术可生产出从皮下组织吸收速度更快的胰岛素类似物。我们报告了12单位皮下注射胰岛素类似物（B9天冬氨酸+B27谷氨酸或B10天冬氨酸）的时效曲线，通过正常血糖钳夹技术（血糖5.0 mmol/L）在健康男性中与人类常规胰岛素进行比较评估。注射12单位任何一种胰岛素制剂后，在最大胰岛素作用（最大葡萄糖输注速率、达峰时间）、输注的葡萄糖总量以及葡萄糖输注速率曲线下面积方面发现了相同的值。与常规胰岛素（56±14分钟，p<0.01）相比，注射改良胰岛素后达到半数最大葡萄糖输注速率的时间明显更早（平均±标准差为38±7和43±5分钟）。注射两种胰岛素类似物45分钟后，葡萄糖输注速率分别增加了7.4±1.8或6.1±1.8 mg·kg-1·min-1，分别反映了常规胰岛素最大作用的83±27%或67±15%。总之，两种测试的胰岛素类似物显示出相似的作用曲线，但与常规胰岛素相比起效明显更快。
